Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption.
about
The critical role of the central nervous system (pro)renin receptor in regulating systemic blood pressureReducing cardiorenal risk through combination therapy with a direct renin inhibitorTherapeutic modalities in diabetic nephropathy: standard and emerging approaches.Aliskiren: the first renin inhibitor for clinical treatmentManagement of Diabetic Nephropathy in the Elderly: Special Considerations.Hemodynamic and hormonal changes to dual renin-angiotensin system inhibition in experimental hypertension.Rationale for combining a direct renin inhibitor with other renin- angiotensin system blockers. Focus on aliskiren and combinations.Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin-angiotensin-aldosterone system: antihypertensive effects and benefits beyond BP control.Additive effects of cilnidipine, an L-/N-type calcium channel blocker, and an angiotensin II receptor blocker on reducing cardiorenal damage in Otsuka Long-Evans Tokushima Fatty rats with type 2 diabetes mellitus.Therapeutic effects of vitamin D analogs on cardiac hypertrophy in spontaneously hypertensive rats.Aliskiren and valsartan combination therapy for the management of hypertension.Aliskiren - an alternative to angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in the therapy of arterial hypertensionRole of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors.Renin and cardiovascular disease: Worn-out path, or new direction.Aliskiren and amlodipine in the management of essential hypertension: meta-analysis of randomized controlled trials.Central Pressure and Biomarker Responses to Renin Inhibition with Hydrochlorothiazide and Ramipril in Obese Hypertensives: The ATTAIN Study.Aliskiren: An orally active renin inhibitor.Role of aliskiren in blood pressure control and renoprotectionFirst-line treatment of hypertension: critical appraisal of potential role of aliskiren and hydrochlorothiazide in a fixed combination.Reversibility of the effects of aliskiren in the renal versus systemic circulation.Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjectsAliskiren in hypertension: evidence for its potential therapeutic valueComparative effects of different modes of renin angiotensin system inhibition on hypercholesterolaemia-induced atherosclerosis.The effect of direct renin inhibition alone and in combination with ACE inhibition on endothelial function, arterial stiffness, and renal function in type 1 diabetes.Potential side effects of renin inhibitors--mechanisms based on comparison with other renin-angiotensin blockers.Urinary albumin excretion and the renin-angiotensin system in cardiovascular risk management.Oral direct renin inhibition: premise, promise, and potential limitations of a new antihypertensive drug.Aliskiren for renin inhibition: a new class of antihypertensives.Molecular mechanism of vitamin D in the cardiovascular systemDirect renin inhibitors: a new approach to antihypertensive drug treatment.Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase.Aliskiren, the future of renin-angiotensin system blockade?The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction.Aliskiren--an orally active renin inhibitor. Review of pharmacology, pharmacodynamics, kinetics, and clinical potential in the treatment of hypertension.Aliskiren-hydrochlorothiazide combination for the treatment of hypertension.Aliskiren, amlodipine and hydrochlorothiazide triple combination for hypertensionRenin inhibition with aliskiren in hypertension: focus on aliskiren/hydrochlorothiazide combination therapyComparison of dual RAAS blockade and higher-dose RAAS inhibition on nephropathy progression.Aliskiren fails to lower blood pressure in patients who have either low PRA levels or whose PRA falls insufficiently or reactively rises.Long-term therapeutic effect of vitamin D analog doxercalciferol on diabetic nephropathy: strong synergism with AT1 receptor antagonist.
P2860
Q26750465-51C9255F-9AB5-4C4F-9267-F789B40771CEQ26851307-90160DD1-3F76-4358-8C6F-A83B32C253DDQ27007027-1A8BE43C-5001-495C-86CD-C63BE0492E6CQ28272666-11450BB2-D6C6-40A6-B63E-1C5A37105A4CQ30353386-2236D2CB-5E28-4E13-AF44-43352195769AQ30415031-9AC43D13-F05D-456B-878F-BB536641A3C2Q30452640-A5E04ED1-73FD-4EE4-A2FA-CF7AFEA870A0Q33783689-B86BC43D-811A-41A5-8F21-30C947081233Q33800185-DF08AC7A-97F7-4D84-A4A4-740554D94262Q34032089-19FF4710-571A-470B-BA41-991A5EE7DD71Q34139070-D818ABD9-6E1A-4EB5-95CA-B6F6772701E8Q34247173-567F87D7-86C3-49D5-A375-65ACE9080991Q34608252-4EC3B97C-F54F-46C6-83C6-5D94B0A15817Q34801804-1BF1CBCE-8D2B-447B-A9C5-64C92C19B943Q34905891-B05F3678-F2DC-452C-9EF9-87A0052538D5Q35005395-5A530FC6-010F-4EC9-A96D-D20D82CCEE42Q35013037-884E26AB-6897-4309-94B6-9922E966B011Q35026735-59B26CEF-4905-4855-9047-0FD4ADC506E6Q35210508-91070686-D2C4-413B-8880-B661F0BE42D5Q35758528-E725B9EA-4F68-4DB8-8B8F-E5B58AF87593Q35827907-0EA2A520-35B1-4D29-80AB-6FE0939DDFE2Q35876368-DF9338BC-B12B-4E0C-8076-9C81DF868592Q36025434-2B39C618-51EC-4669-BFD1-1EEB9650B9A7Q36334722-F8495F29-2750-40B8-BC87-5A91ED0F0BF2Q36565036-3E43C722-482F-4B30-B931-AA8100489558Q36675396-85C4EC2C-1F52-4A88-9EF6-BA06419A841FQ36688756-FD529012-1A31-439E-8D6C-4451E2148863Q36753093-4E9624A2-B637-4CEE-A02D-4CC6D4BF04F7Q36821166-DEFB7162-35F2-415C-90FF-DF03F668CAFBQ36900799-EBEFAC86-E824-48A1-977E-25369FA79CF2Q36924964-AD78500D-F7C6-41BA-81B3-AF1B9DD8F78DQ36941829-AA441A30-1D59-446F-A905-4ED60781FF1CQ37019887-FFC00131-2E34-4634-8DC5-853D49F6352BQ37058900-5794ACB2-7A42-46EB-A2EC-B41C74AE176EQ37104856-06BD41F2-E97F-46B2-9276-A66B82DE8DADQ37125703-C79AD68F-BFE5-4360-8572-5F9DC981EC26Q37145704-63E66CAF-E66E-4812-B20B-061611FB5630Q37158325-610ED656-2D1F-4F55-A539-B811BBE38FE4Q37273294-C27FCD50-A5C6-4F8E-8A7A-E1A4FBDCD96FQ37337349-604193D1-0058-42A1-AC19-7967950E3BD1
P2860
Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Pharmacologic demonstration of ...... I-renin feedback interruption.
@en
Pharmacologic demonstration of ...... I-renin feedback interruption.
@nl
type
label
Pharmacologic demonstration of ...... I-renin feedback interruption.
@en
Pharmacologic demonstration of ...... I-renin feedback interruption.
@nl
prefLabel
Pharmacologic demonstration of ...... I-renin feedback interruption.
@en
Pharmacologic demonstration of ...... I-renin feedback interruption.
@nl
P2093
P1476
Pharmacologic demonstration of ...... I-renin feedback interruption.
@en
P2093
Alessandra Bura-Rivière
Alvine Bissery
Joël Ménard
Michel Azizi
Riccardo P Camisasca
Sujata Vaidyanathan
Than-Tam Guyenne
P304
P356
10.1097/01.ASN.0000146686.35541.29
P577
2004-12-01T00:00:00Z